Natco Pharma

Natco Pharma Q2FY25 results: PAT jumps 83% to Rs 676 cr on robust sales

Natco Pharma on Tuesday said its consolidated net profit jumped 83 per cent on-year to Rs 676 crore in the September 2024 quarter, aided by robust sales. The drug maker reported a net profit of Rs 369 crore in the July-September period of last fiscal. Revenue from operations rose to Rs 1,371 crore as compared with Rs 1,031 crore in the year-ago period, the company said in a regulatory filing. "The company has shown continued strong growth during the second quarter driven by exports formulation business and stable domestic pharmaceutical business," it stated. The company said its board has declared a second interim dividend of Rs 1.5 per equity share of Rs 2 each for financial year 2024-25. Shares of the drug firm ended 0.19 per cent down at Rs 1,393.15 apiece on the BSE.

Here's why Natco Pharma share price gained over 4% on October 7; details

Natco Pharma share rose after the company announced that Mylan Pharmaceuticals Inc & Novo Nordisk have reached a settlement of the US patent litigation related to generic Ozempic (Semaglutide)

Natco Pharma shares hit all time high, extend gain for second day; details

The Natco Pharma share price has surged nearly 20 per cent in the last one month, and by 92 per cent year to date

Natco Pharma stock rises 3% after subsidiary invests $8 mn in biotech firm

Natco Pharma share price rose after the company on Wednesday announced that its wholly owned Canadian subsidiary, NATCO Pharma Inc, has made an investment of $8 million in eGenesis

Natco Pharma rises 4% after filing ANDA for generic lung cancer drug

Natco Pharma is the first company to have filed a substantially complete ANDA for a generic cancer drug

Natco Pharma stock surges 8%, hits new 52-week high on strong Q4 show

On Monday, Natco Pharma reported a 40.1 per cent year-on-year (YoY) surge in net profit, totaling Rs 386.3 crore in Q4FY23, up from Rs 275.8 crore

Q4 results today: LIC, NMDC, AstraZeneca among 303 firms to post earnings

Q4 FY24 company results: Elgi Equipments, Natco Pharma, Nalco, Goodyear India, and IFB Ind will be releasing their fourth quarter report on May 27

USFDA pulls up Natco Pharma for several violations at Telangana plant

Natco Pharma failed to maintain cleanliness, sterilise equipment and utensils at appropriate intervals at its Telangana-based plant, as per the US health regulator. In the warning letter to the company, US Food and Drug Administration said its investigators observed various violations at the finished pharmaceuticals plant located at Kothur Village in Telangana. The USFDA inspected the facility from October 9 to 18, 2023. "Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and/or sterilise equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements," the US health regulator noted. It further said: "Your cleaning procedure for your non-dedicated equipment is inadequate." Cross-contamination is not uniform, and the testing of control samples and placebo batches failed to ...

Natco Pharma receives warning letter from USFDA for Telangana plant

Natco Pharma on Tuesday said it has received a warning letter from the US health regulator for its Telangana-based manufacturing plant. The US Food and Drug Administration (USFDA) had issued eight observations under Form 483 after inspecting the company's Kothur-based formulation facility. The inspection was conducted by USFDA from October 9 to October 18, 2023. "We wish to inform you that the company has received a warning letter dated April 8, 2024 from the USFDA," the drug firm said in a regulatory filing. The company does not believe that the warning letter will have an impact on supplies or the existing revenues from this facility, it added. "It may cause delay/withholding of pending product approvals from this site," Natco Pharma said. The drug firm will respond to the letter within the stipulated timelines and work closely with the USFDA to address the concerns in a holistic and timely manner to ensure sustained compliance, it said. A warning letter is issued when the US

Natco Pharma Q3 results: Net profit rises over 3-fold to Rs 212.7 crore

Natco Pharma Ltd on Wednesday reported over three-fold rise in consolidated net profit at Rs 212.7 crore in the third quarter ended December 31, 2023 on the back of robust revenue growth. The company had posted a consolidated net profit of Rs 62.3 crore in the same period last fiscal, Natco Pharma said in a regulatory filing. Consolidated revenue from operations in the quarter under review stood at Rs 758.6 crore, as against Rs 492.5 crore in the year-ago period, it added. Total expenses were higher at Rs 539.3 crore, up from Rs 431.9 crore in the same quarter last fiscal, the company said. There was strong growth across businesses compared to last year, Natco said, adding it is confident of its strategy going forward. Revenue from export of formulations was at Rs 605.6 crore in the third quarter, up from Rs 333.7 crore in the year-ago period. However, domestic formulations revenue was down at Rs 99.4 crore, as compared to Rs 101.1 crore in the corresponding period last fiscal, i

Natco Pharma Q2 results: Net profit surges over 6-fold to Rs 369 cr

Natco Pharma on Tuesday reported an over six-fold jump in its consolidated net profit to Rs 369 crore in the second quarter ended September 30, 2023. The Hyderabad-based drug firm had reported a net profit of Rs 57 crore in the July-September period of last fiscal. Consolidated total revenue rose to Rs 1,061 crore for the period under review, as compared with Rs 453 crore in the year-ago period, Natco Pharma said in a regulatory filing. The company reported strong performance during the quarter due to growth in formulation exports and increased sales in the domestic agrochemical business, it added.

Natco Pharma, Celgene Corp, others sued in US for generic cancer drug

Natco Pharma on Friday said the company and other drug makers have been named defendants in an antitrust lawsuit regarding a generic cancer treatment drug in the US. The Hyderabad-based drug firm along with Celgene Corporation, Bristol Myers Squibb, Breckenridge Pharmaceutical Inc and others have been named defendants by Louisiana Health Service & Indemnity Company, D/B/A Blue Cross and Blue Shield of Losisiana and HMO Louisiana Inc, regarding anti-cancer treatment medication Pomalidomide. The company believes this matter is without merit, Natco Pharma said in a statement. Breckenridge is the abbreviated new drug application (ANDA) holder and distribution partner for the generic product in the US, it added. Natco Pharma shares were trading 3.13 per cent down at Rs 885.00 apiece on the BSE.

Natco Pharma's net profit rises 31.2% to Rs 420.3 cr in June quarter

Natco Pharma Ltd on Wednesday reported a 31.2 per cent rise in consolidated net profit at Rs 420.3 crore in the first quarter ended June 30, 2023. The company had posted a consolidated net profit of Rs 320.4 crore in the same period last fiscal, Natco Pharma said in a regulatory filing. Consolidated revenue from operations during the quarter under review stood at Rs 1,140.5 crore as against Rs 884.6 crore in the year-ago period, it added. Total expenses were higher at Rs 660.2 crore as compared to Rs 533.1 crore a year ago. The major drivers of business during the June quarter were formulation exports, strong growth in domestic business of both pharma and agro, and steady sales from subsidiaries, the company said. Exports of formulations clocked Rs 884.2 crore in the April-June quarter from Rs 736.9 crore a year ago, while domestic formulations registered Rs 132.4 crore, up from Rs 88.5 crore last year, it added. The active pharmaceutical ingredients segment posted Rs 75.1 crore,

Stocks to watch: Tata Steel, NMDC, PNC Infra, Natco Pharma, MTAR Tech

Stocks to watch on June 19, 2023: From Tata Steel to NMDC, here are the top stocks to watch in Monday's trading session

Natco Pharma to set up subsidiary in Indonesia with investment of $3 mn

Natco Pharma Ltd on Thursday said its board has approved setting up of a subsidiary in Indonesia with an investment of up to USD 3 million (nearly Rs 25 crore) for selling pharmaceutical products in that country. The new subsidiary -- PT. NATCO Lotus Farma -- will be a joint venture with Natco holding 51 per cent and the balance stake 49 per cent by PT. Mitra Medis Exim (MME), a part of Mitra Jaya Group, which is a 40 year old multi-diversified group, as the co-promoter, the company said in a regulatory filing. The company's board approved the proposal at its meeting held on Thursday. Natco will initially invest USD 1 million for a stake of 51 per cent as capital contribution and balance will be invested as and when the funds are required by the subsidiary, it added. PT. NATCO Lotus Farma will be engaged in selling pharmaceutical products in Indonesia, it added. MME is in the business of distribution for active pharmaceutical ingredients and excipients for end-users in Indonesia.

Natco Pharma jumps 4% on filing generic version of oncology drug in US

The drug major filed an abbreviated new drug application (ANDA) for generic versions of Olaparib tablets - 100 mg and 150 mg with the US Food and Drug Administration (USFDA)

Breather for Natco in Novartis cardiac drug case from Delhi High Court

May open floodgates for Indian drugmakers to launch the generic version of the drug as early as next week

Broad-based rally lifts Sensex 578pts, Nifty above 17,800; pharma stks lead

CLOSING BELL: Besides, the Nifty Auto and Private Bank indices advanced 1.7 per cent each

Stocks to Watch: IRCTC, McLeod Russel, Sugar, Adani Ports, Gail, Dish TV

Stocks to Watch Today: Oil related shares are likely to be in focus on Tuesday as the oil ministry sought a review of the windfall profit tax on domestically produced crude oil.

Stocks to Watch: GAIL, Sona BLW, ONGC, Natco Pharma, RIL, Airtel, Vodafone

Stocks to Watch: Blackstone Inc. is seeking to raise as much as Rs 3,180 crore ($400 million) through the sale of shares in Indian automotive component maker Sona Comstar